Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma

Journal of Pediatric Hematology/Oncology

Volumn 28, Issue 2, 2006, Pages 64-68

  Shimasaki, Noriko ^a   Mori, Tetsuya ^a   Samejima, Hazuki ^a   Sato, Reiko ^a   Shimada, Hiroyuki ^a   Yahagi, Naohisa ^a   Torii, Chiharu ^a   Yoshihara, Hiroki ^a   Tanigawara, Yusuke ^a   Takahashi, Takao ^a   Kosaki, Kenjiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Methotrexate; Methylenetetrahydrofolate reductase (MTHFR); Polymorphism; Reduced folate carrier 1 (RFC1); Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINOTRANSFERASE; FOLINIC ACID; HYDROCORTISONE; METHOTREXATE; REDUCED FOLATE CARRIER; REDUCED FOLATE CARRIER 1; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLELE; ARTICLE; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; HUMAN; LEUKOENCEPHALOPATHY; LYMPHOBLASTOMA; LYMPHOMA; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; VOMITING;

ADOLESCENT; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC DISEASES; HEPATITIS, TOXIC; HUMANS; INFANT; JAPAN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, LYMPHOBLASTIC; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; STOMATITIS; VARIATION (GENETICS);

EID: 33644625067     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mph.0000198269.61948.90     Document Type: Article

References (25)

1. Jonsson G, Kamen A. Methotrexate and childhood leukemia. Cancer Invest. 1991;9:53-60.
2. Relling V, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol. 1994;12:1667-1672.
3. Rask C, Albertioni F, Bentzen S, et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia. Acta Oncol (Madr). 1998;37:277-284.
4. Frosst P, Blom J, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-113.
5. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol. 2002;13:1915-1918.
6. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231-234.
7. van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatol. 2002;41:658-665.
8. Toffoli G, Russon A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer. 2003;103:294-299.
9. Kishi S, Giener J, Cheng C, et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003;21:3084-3091.
10. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G>A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab. 2000;70:310-315.
11. Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002;100:3832-3834.
12. Tsuchida M, Ikuta K, Hanada R, et al. Long-term follow-up of childhood acute lymphoblastic leukemia in Tokyo Children's Cancer Study Group 1981-1995. Leukemia. 2000;14:2295-2306.
13. Common toxicity criteria version 2.0 [National Cancer Institute Web site]. April 30, 1999. Available at: http://ctep.info.nih.gov/reporting/CTC-3. html. Accessed May 1, 2003.
14. Shimada H, Mori T, Shimasaki N, et al. Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia. Leukemia. 2004;18:1142-1144.
15. Kosaki K, Suzuki T, Muroya K, et al. PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome. J Clin Endocrinol Metab. 2002;87:3529-3533.
16. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
17. Hanley JA, Negassa A, Edwardes MD, et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157:364-375.
18. Wang Y, Zhao R, Russell R, et al. Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochim Biophys Acta. 2001;1513:49-54.
19. Ramaekers VT, Hausler M, Opladen T, et al. Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. Neuropediatrics. 2002;33:301-308.
20. Wong SC, Proefke SA, Bhushan A, et al. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem. 1995;270:17468-17475.
21. Lorenzi AR, Johnson AH, Gough A. Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription. Rheumatology (Oxford). 2000;39:812-813.
22. Chiao JH, Roy K, Tolner B, et al. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem. 1997;272:11165-11170.
23. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis. 1996;19:589-594.
24. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62:3144-3150.
25. Stark M, Rothem L, Jansen G, et al. Antifolate resistance associated with loss of MRP1 expression and function in Chinese hamster ovary cells with markedly impaired export of folate and cholate. Mol Pharmacol. 2003;64:220-227.